Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study-Reference-Cited by-同舟云学术

Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study

Published:2021-12 Issue: Volume: Page:
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Briggs Andrew,Wehler Beth,Gaultney Jennifer G.,Upton Alex,Italiano Antoine,Bokemeyer Carsten,Paracha Noman,Sullivan Sean D.

Funder

Pharmaceuticals Bayer

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference26 articles.

1. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features;Bongarzone;Clin Cancer Res,1998

2. Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs;Haslem;Oncotarget,2018

3. A retrospective analysis of precision medicine outcomes in patients with advanced cancer reveals improved progression-free survival without increased health care costs;Haslem;J Oncol Pract,2017

4. Neurotrophin trk receptors: new targets for cancer therapy;Meldolesi;Rev Physiol Biochem Pharmacol,2018

5. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States;Prasad;Cancer,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study;Value in Health;2024-07

2. Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands;Molecular Diagnosis & Therapy;2024-04-14

3. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK;Journal of Medical Economics;2024-02-19

4. Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions;Value in Health;2023-11

5. Why will there never be a randomized trial for NTRK-rearranged tumors?;Annals of Oncology;2023-07